Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

The following is a summary of “Annual variant-targeted vaccination to prevent severe COVID-19 disease in cohorts with vaccine-derived and hybrid immunity,” published in the March 2025 issue of ...

A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

The virus that causes COVID-19 continues to mutate. Scientists say that's likely to continue indefinitely, and the virus will ...

According to a study of the COVICAT cohort, almost one in four people infected with SARS-CoV-2 suffered from long-COVID. Long ...

Starting from April 8, people aged 65 and older, indigenous people aged 55 to 64, children younger than six months old and ...

Long COVID symptoms persisted for up to two years in more than half of the individuals who experienced the condition, according to new research published in BMC Medicine.

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...